The University of California has synthesized proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cancer, atherosclerosis and stroke.
Hyundai Pharmaceutical Co. Ltd. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.
Neuromyelitis optica spectrum disorder (NMOSD) is neuroinflammatory disease characterized by optic neuritis and myelitis with presence of anti-aquaporin-4 (AQP4) antibodies. Satralizumab is an anti-IL-6 receptor (IL-6R) humanized antibody approved for preventing relapses in NMOSD (AQP4 IgG positive) in adults and children in Japan.
Researchers at Alligator Bioscience AB and Lund University have developed a bispecific therapeutic antibody, ATOR-4066, that simultaneously targets the immune cell receptor CD40 and the tumor antigen CEACAM5.
Athernal Bio Ltd. has launched, supported by £3.5 million (US$4.7 million) in funding and with a focus on the development of targeted immunotherapies for early intervention in high-risk clonal hematopoiesis, a cancer precursor condition which can lead to acute myeloid leukemia (AML) and other hematological cancers.
Mercury Bio Inc. has released promising results from a preclinical study that successfully utilized its extracellular vesicle (EV) drug encapsulation platform (yEV) to deliver proteins, in the form of nanobodies, into neurons across the blood-brain barrier. The yEV platform utilizes yeast-derived exosomes, a subtype of EV.
Researchers from Nanjing Chengshi (TheraRNA) Biomedical Technology Co. Ltd. and collaborators have developed a novel ionizable lipid, C14-192, that features a 3-oxo-polyamine head group.
Pop Biotechnologies Inc. has been awarded a $2.46 million grant by the National Institutes of Health (NIH) to pursue development of a ‘mosaic’ active immunotherapy against Alzheimer’s disease.
Appili Therapeutics Inc. and its partner Vitalex Biosciences LLC have announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded up to $40 million in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections.
Human rhinovirus (HRV) is the most frequent cause of upper respiratory infections and a key trigger of asthma exacerbations. No effective anti-HRV therapies exist, and vaccine efforts have been unsuccessful due to its extreme genetic and antigenic diversity, with over 160 known serotypes.
RSS
